IMMUNODULATION OF MACROPHAGE FOLLOWING TRAUMA
创伤后巨噬细胞的免疫
基本信息
- 批准号:2684967
- 负责人:
- 金额:$ 18.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1991
- 资助国家:美国
- 起止时间:1991-04-01 至 1999-03-31
- 项目状态:已结题
- 来源:
- 关键词:CD antigens adult respiratory distress syndrome alveolar macrophages antioxidants biological signal transduction calcium flux confocal scanning microscopy gene expression human tissue inflammation interferon gamma laboratory rabbit leukocyte activation /transformation lipopolysaccharides northern blottings nuclear factor kappa beta phosphorylation platelet activating factor protein kinase A protein kinase C receptor expression tissue /cell culture trauma tumor necrosis factor alpha
项目摘要
Trauma remains a major cause of death and disability in America, and, the
number one cause of mortality in the one to forty-five year old age group
and for loss of productive years of life overall. In turn, the major cause
of late death following trauma is organ dysfunction, including ARDS,
leading to multiple organ failure syndrome (MOFS) and death. The primary
etiology of ARDS and MOFS is the clinical "sepsis syndrome" or systemic
inflammatory response syndrome (SIRS) causing disseminated tissue injury
and organ dysfunction. The long lived, highly diverse tissue-fixed
macrophage is a crucial central coordinator of both the normal and
aberrant host immunoinflammatory response and is responsible for the
induction and persistence of the "malignant systemic inflammatory
response" seen in MOFS. The macrophage is both "primed" and activated by
a multitude of stimuli in the inflammatory milieu. Until now therapeutic
approaches have focused on control or inhibition of single components of
the overall inflammatory response. However, since the inflammatory
response is so replete with redundance and feedback amplification
mechanisms, it is appealing to broaden our focus to more generally control
the inflammatory injury. To achieve this goal, we propose to better define
the cellular mechanisms of macrophage activation and develop therapeutic
interventions based on modulation of the over-aggressive macrophage
immunoinflammatory response.
Hypothesis: The aberrant macrophage inflammatory response can be modulated
by manipulation of cellular signal transduction mechanisms that control
inflammatory mediator genes. Elucidation and control of these macrophage
cellular mechanisms will permit development of safe therapeutic
interventions to potentially prevent ARDS, MOFS and death.
To test this hypothesis the following specific aims will be pursued: l.)
delineate and confirm the proposed components of the macrophage-LPS signal
transduction pathway, 2.) elucidate the molecular mechanisms of "priming"
(reprogramming) and/or autocrine augmentation of the macrophage response,
3.) determine the feasibility and effects of selectively modifying binding
and uptake of LPS by stimulatory (CD14) and non-stimulatory (scavenger,
acyl-LDL) receptors 4.) investigate the contribution of phospholipid
metabolism to macrophage activation, 5.) evaluate the calcium-calmodulin
(Ca-CaM) pathway in macrophage activation, and 6.) test the ability of
antioxidants to alter inflammatory stimulus-signal transduction in the
macrophage.
Elucidation of the mechanisms controlling the macrophage response to
inflammatory stimuli will permit development of therapeutic interventions
to beneficially modulate the excessive macrophage and the subsequent host
auto-destructive responses.
创伤仍然是美国死亡和残疾的主要原因,
1至45岁年龄组的头号死亡原因
以及生产性寿命的总体损失。反过来,主要原因
创伤后晚期死亡的原因是器官功能障碍,包括ARDS,
导致多器官衰竭综合征(MOFS)和死亡。主
ARDS和MOFS的病因是临床“脓毒症综合征”或全身性
炎症反应综合征(SIRS)导致播散性组织损伤
和器官功能障碍寿命长,高度多样化的组织固定
巨噬细胞是一个重要的中央协调员,
异常的宿主免疫炎症反应,并负责
“恶性全身性炎症”的诱导和持续
在MOFS中看到的“响应”。巨噬细胞是“启动”和激活的,
炎症环境中的多种刺激。到目前为止治疗
方法集中在控制或抑制单组分的
整体炎症反应。然而,由于炎症
反应是如此充满了冗余和反馈放大
机制,它呼吁扩大我们的重点,以更普遍的控制
炎性损伤。为了实现这一目标,我们建议更好地定义
巨噬细胞活化的细胞机制和开发治疗
基于调节过度侵袭性巨噬细胞的干预措施
免疫炎症反应。
假设:异常的巨噬细胞炎症反应可以被调节
通过操纵细胞信号转导机制,
炎症介质基因。阐明和控制这些巨噬细胞
细胞机制将允许开发安全的治疗方法,
可能预防ARDS、MOFS和死亡的干预措施。
为了检验这一假设,将追求以下具体目标:
描绘并确认巨噬细胞-LPS信号的拟议成分
转导途径,2.)阐明“引发”的分子机制
(重编程)和/或巨噬细胞应答的自分泌增强,
3.)第三章确定选择性修改绑定的可行性和效果
以及刺激性(CD 14)和非刺激性(清除剂,
酰基-LDL)受体4.)研究磷脂的贡献
代谢至巨噬细胞活化,5.)评价钙-钙调素
(Ca-CaM)途径,和6.)测试的能力
抗氧化剂改变炎症刺激信号转导,
巨噬细胞
阐明控制巨噬细胞对
炎症刺激将允许开发治疗干预
以有益地调节过量的巨噬细胞和随后的宿主
自我毁灭反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ronald Vitt Maier其他文献
Ronald Vitt Maier的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ronald Vitt Maier', 18)}}的其他基金
IMMUNOMODULATION OF MACROPHAGES FOLLOWING TRAUMA
创伤后巨噬细胞的免疫调节
- 批准号:
6179352 - 财政年份:1991
- 资助金额:
$ 18.55万 - 项目类别:
IMMUNOMODULATION OF MACROPHAGES FOLLOWING TRAUMA
创伤后巨噬细胞的免疫调节
- 批准号:
7068451 - 财政年份:1991
- 资助金额:
$ 18.55万 - 项目类别:
IMMUNOMODULATION OF MACROPHAGES FOLLOWING TRAUMA
创伤后巨噬细胞的免疫调节
- 批准号:
3305342 - 财政年份:1991
- 资助金额:
$ 18.55万 - 项目类别:
IMMUNOMODULATION OF MACROPHAGES FOLLOWING TRAUMA
创伤后巨噬细胞的免疫调节
- 批准号:
6895829 - 财政年份:1991
- 资助金额:
$ 18.55万 - 项目类别:
IMMUNOMODULATION OF MACROPHAGES FOLLOWING TRAUMA
创伤后巨噬细胞的免疫调节
- 批准号:
2183477 - 财政年份:1991
- 资助金额:
$ 18.55万 - 项目类别:
IMMUNOMODULATION OF MACROPHAGES FOLLOWING TRAUMA
创伤后巨噬细胞的免疫调节
- 批准号:
3305344 - 财政年份:1991
- 资助金额:
$ 18.55万 - 项目类别:
IMMUNOMODULATION OF MACROPHAGES FOLLOWING TRAUMA
创伤后巨噬细胞的免疫调节
- 批准号:
6619032 - 财政年份:1991
- 资助金额:
$ 18.55万 - 项目类别:
IMMUNOMODULATION OF MACROPHAGES FOLLOWING TRAUMA
创伤后巨噬细胞的免疫调节
- 批准号:
6749535 - 财政年份:1991
- 资助金额:
$ 18.55万 - 项目类别:
相似海外基金
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6564818 - 财政年份:2001
- 资助金额:
$ 18.55万 - 项目类别:
ADHESION MOLECULES IN ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征中的粘附分子
- 批准号:
6410976 - 财政年份:2000
- 资助金额:
$ 18.55万 - 项目类别:
TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的治疗
- 批准号:
6370267 - 财政年份:2000
- 资助金额:
$ 18.55万 - 项目类别:
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6418789 - 财政年份:2000
- 资助金额:
$ 18.55万 - 项目类别:
TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的治疗
- 批准号:
6370266 - 财政年份:2000
- 资助金额:
$ 18.55万 - 项目类别:
TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的治疗
- 批准号:
6370265 - 财政年份:2000
- 资助金额:
$ 18.55万 - 项目类别:
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6302122 - 财政年份:1999
- 资助金额:
$ 18.55万 - 项目类别:
ADHESION MOLECULES IN ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征中的粘附分子
- 批准号:
6309780 - 财政年份:1999
- 资助金额:
$ 18.55万 - 项目类别:
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6109540 - 财政年份:1998
- 资助金额:
$ 18.55万 - 项目类别:
ADHESION MOLECULES IN ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征中的粘附分子
- 批准号:
6265845 - 财政年份:1998
- 资助金额:
$ 18.55万 - 项目类别:














{{item.name}}会员




